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Background: Individuals with hemophilia require lifelong specialized care. As the lifespan for 
individuals with hemophilia has increased, patients must transition from pediatric to adult 
providers. Research has shown that individuals with hemophilia face multiple barriers during this 
transition of care and have decreased prophylaxis regimen compliance which can have lifelong 
negative effects. In this study, we seek to determine the impact of transition of care on 
hemophilia patients who receive treatment at the Hemophilia Center of Western Pennsylvania 
(HCWP).  
Methods: The medical records of a cohort of patients at the HCWP, aged 26 to 30, were 
reviewed from age 15 to their current age. Information was gathered about comprehensive visit 
compliance, bleeding events, and insurance coverage. Statistical analyses were performed using 
linear regression and summary statistics.  
Results: 26 patients with hemophilia who were treated at the HCWP were included in this study. 
Statistical analysis did not provide evidence to suggest that there is a linear relationship between 
age and comprehensive visit compliance or age and bleeding events. 42.3% of the participants 
had at least one confirmed lapse in insurance during the time period studied.  
Conclusions: The transition from pediatric to adult care providers in patients with hemophilia, 
treated at the HCWP, did not have an impact on comprehensive visit compliance or bleeding. 
 v 
Lapses in health insurance coverage are a common problem for individuals with hemophilia after 
age 18. Further research is needed to determine effective interventions to increase 
comprehensive visit compliance at all ages and interventions to increase health insurance 
coverage of adults.  
Public Health Significance: Comprehensive visit compliance is important for monitoring the 
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The lifespan of individuals with hemophilia has greatly increased since the 1950s which 
has led to the need for comprehensive care of adults with this condition. This has created the need 
to transition patients from seeing pediatric specialists to adult specialists as they reach adulthood. 
The American Academy of Pediatrics policy statement, A Consensus Statement on Health Care 
Transitions for Young Adults With Special Health Care Needs, states that “the goal of transition in 
health care for young adults with special health care needs is to maximize lifelong functioning and 
potential through the provision of high-quality, developmentally appropriate health care services 
that continue uninterrupted as the individual moves from adolescence to adulthood.”1 This 
transition of care can be difficult for patients as it comes at a time of numerous life changes and 
the patient must take responsibility for his healthcare. Studies have shown that a difficult transition 
can result in decreased compliance and decline in quality of life and/or overall health for 
adolescents with chronic illness.2 To try and address this transition for patients with hemophilia, 
the National Hemophilia Foundation published the Transition Guidelines for People with Bleeding 
Disorders in 2003. This document was developed to be used at Hemophilia Treatment Centers to 
help individuals with a bleeding disorder through many types of transitions including “acceptance 
of the bleeding disorder, self-care, progressing though school, vocational/career planning, moving 
to an adult center, starting a family, middle age and retirement.”2 
While there have been guidelines published outlining the transition of care in individuals 
with hemophilia, little research has been done to evaluate how patients are impacted by this 
transition. This study aims to examine the impact of this transition on patients with hemophilia 
who receive treatment at the Hemophilia Center of Western Pennsylvania (HCWP). We 
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investigated how this transition impacts patient care by studying their rates of bleeds, insurance 
coverage, and attendance at clinic before, during, and after this transition. We hypothesized that 
individuals will be negatively impacted by transitioning from pediatric to adult care. This study 
aimed to identify where efforts should be focused to improve the transition for patients with 
hemophilia as they reach adulthood. The specific aims of the study were to: 
• Determine if there is a difference in rates of acute bleeding events in patients with 
hemophilia A or hemophilia B before, during, and after transitioning from pediatric to 
adult care providers 
• Determine if there is a difference in attendance rates at clinic visits in patient with 
hemophilia A or hemophilia B before, during, and after transitioning from pediatric to 
adult care providers 
• Characterize lapses in insurance coverage in patients with hemophilia A or hemophilia B 
before, during, and after transitioning from pediatric to adult care providers 
This study was carried out by reviewing the electronic medical records of males age 26-
30, diagnosed with hemophilia A or hemophilia B, who received treatment at the HCWP. We 
retrospectively examined medical records to record the number of acute bleeding events, annual 
comprehensive clinic attendance, and insurance coverage for before, during, and after transitioning 
from pediatric to adult care. We also collected additional information from the medical record 
including race, ethnicity, hemophilia type, hospitalizations, treatment, inhibitor development, and 
joint disease for use during statistical analysis.  
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2.0 Literature Review 
2.1 Overview of Hemophilia 
Hemophilia is an X-linked inherited coagulation disorder that is caused by pathogenic 
variants in clotting factor genes. Individuals with hemophilia A have pathogenic variants in the F8 
gene, which is responsible for making Factor VIII. Individuals with hemophilia B have pathogenic 
variants in the F9 gene, which is responsible for making Factor IX.  Hemophilia A prevalence in 
the United States is estimated at 1:6,500 live births.3 The prevalence of hemophilia B is estimated 
at 1:30,000 live births, thus making hemophilia A about five times more prevalent than hemophilia 
B.4 It is estimated that there are 20,000 individuals living with hemophilia in the United States.5 
Hemophilia severity is classified by the measured factor concentration in the blood. Severe 
hemophilia is defined as <1% of normal factor concentration. Individuals with severe hemophilia 
typically have spontaneous bleeding into muscles and joints without an identifiable cause. 
Moderate hemophilia is defined as 1-5% of normal factor concentration. Individuals with moderate 
hemophilia typically have prolonged bleeding with minor trauma or surgery and occasional 
spontaneous bleeding. Mild hemophilia is defined as 5-<40% of normal factor concentration. 
Individuals with mild hemophilia rarely have spontaneous bleeding but have severe bleeding with 
major trauma or surgery.6; 7 
Since hemophilia A and B are X-linked disorders, they typically affect males, while 
females are carriers. The expected mean clotting factor level in a female hemophilia carrier is 50% 
of the healthy population clotting factor level. Most female carriers are asymptomatic. Female 
carriers who have clotting factor levels that are 40-60% of the expected man clotting factor level  
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may have an increased bleeding tendency.8 Approximately 30% of carrier females have clotting 
factor levels <40% which fall into the hemophilia range and may be symptomatic.9; 10 In rare cases 
of significant non-random x-inactivation, carrier females may present with moderate to severe 
hemophilia.8 There are also rare cases where females are compound heterozygotes and can present 
with any severity of hemophilia. Females who are found to have low clotting factor levels, and are 
symptomatic, should be characterized as having hemophilia and should be treated accordingly.7   
2.1.1  Historical Overview 
The history of hemophilia goes back to ancient times. The Talmud, a book of Jewish 
teachings from the second century AD, has the first mention of hemophilia. It states that boys who 
have had two brothers die from prolonged bleeding after circumcision should not be circumcised. 
Albucasis, a 12th century Arabic physician, was the first medical professional to describe a family 
whose males died from bleeding after minor injury.11 
The first modern description of hemophilia was written by Philadelphian physician John 
Conrad Otto in 1803. He published “an account of an hemorrhagic disposition existing in certain 
families,” but he did not yet use the term hemophilia.12 He recognized many of the cardinal features 
of the disorder including that it was hereditary, affected mostly males, and was passed through a 
family by healthy females.12 The term “haemophilia” first appeared in 1828 when Freidrish Hopff 
from the University of Zurich published an essay on the disease.11 
Hemophilia is sometimes referred to as “the royal disease” due to its history of being found 
in European royalty. The Queen of England from 1837 to 1901, Queen Victoria, was a hemophilia 
B carrier.13 Leopold, Queen Victoria’s son, had the disease and had frequent hemorrhages. 
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Hemophilia B was passed on to the Russian, Spanish, and German royal families, by Queen 
Victoria’s daughters, Alice and Beatrice.14 
The cause of hemophilia was not found until the late 1930s. The original theory was that 
the bleeding tendency in hemophilia was due to fragile blood vessels and platelets were thought to 
be a likely cause. In 1937, scientists at Harvard, Patek and Taylor, discovered anti-hemophilia 
globulin, a substance that could be extracted from plasma which could correct the coagulation 
defect in hemophilia. Another big breakthrough came from the scientist Pavlosky from Buenos 
Aires in 1944. He discovered that hemophilia was two separate diseases, hemophilia A and B. He 
found that transferring blood from one hemophilia patient, to another hemophilia patient, would 
correct the coagulation defect after he happened upon patients with different factor deficiencies. 
Both of these discoveries would be fundamental in the future diagnosis and treatment of 
hemophilia.15 
In the 1950s and 1960s, hemophilia was treated with whole blood or fresh plasma 
transfusions. These transfusions did not contain enough factor VIII or factor IX to stop severe 
bleeding. Since severe bleeding still occurred, those with severe hemophilia died in childhood or 
early adulthood.15 This lifespan was an improvement from before treatment with transfusion, as 
previously children with hemophilia rarely survived past the first decade.16 In 1964, Judith Pool 
discovered that the fraction cryoprecipitated from plasma contained large amounts of factor VIII.17 
This cryoprecipitate revolutionized treatment for hemophilia. Treatment with rather small 
volumes, could now control severe bleeding and allow hemostatic control for major surgeries.15 
Even after this discovery, modern management of hemophilia did not begin until the 1970s. 
The 1970s saw the “increased availability of lyophilized plasma concentrates of coagulation 
factors and the widespread adoption of home replacement therapy which led to the early control 
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of hemorrhages and the reduction of musculoskeletal damage typical of untreated or poorly treated 
patients.”15 Also, Sweden began the use of primary prophylaxis, with the goal of preventing 
bleeding episodes and reducing the impact of arthropathy.18 As the need for emergency treatment 
lessened, hemophilia treatment centers began to focus more on comprehensive care from a 
multidisciplinary team. Patients began to more frequently have elective surgeries, most commonly 
orthopedic operations to correct musculoskeletal abnormalities from poorly treated bleeds. In 
1977, the drug desmopressin was discovered as a treatment for mild hemophilia A. This treatment 
helped reduce the need for plasma-derived products and lowered treatment costs for patients with 
mild hemophilia A.19 
Unfortunately, the “golden age” of hemophilia treatment of the 1970s came to an end in 
the early 1980s. During this time, 60-70% of individuals with severe hemophilia became infected 
with human immunodeficiency virus (HIV) because factor concentrates, generated from pooled 
plasma derived from thousands of individuals, were contaminated with the virus. For the same 
reason, during this time, almost all patients with hemophilia were infected with hepatitis C if they 
received factor concentrates.20 Plasma from thousands of donors was used to manufacture factor 
concentrates, and there was no screening or viral inactivation of donated blood products in place. 
Many individuals suffered from sequelae of these infections and there was a great need for the safe 
treatment of hemophilia. To control the spread of infection, viral inactivation techniques were 
developed and implemented in plasma-derived factor concentrate production. Additionally, there 
were methods adopted, such as nucleic acid testing, to screen blood donation for viruses. As a 
result of these changes, there has not been transmission of HIV or hepatitis viruses in plasma-
derived factor concentrates since the late 1980s; however the fear of possible transmission of new 
or unknown pathogens in blood products remains.15 
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While the hemophilia community was suffering the devastating impacts of these blood-
borne infections, great scientific advancements were made for hemophilia treatment. In 1982, the 
F9 gene was cloned for the first time. Cloning of the F8 gene came soon after in 1984. The cloning 
of these genes allowed for the industrial production of recombinant factor VIII and IX.21 The first 
report of clinical efficacy of recombinant factor in two hemophilia A patients was published in 
1989.22 Recombinant factor went on to become widely used to treat patients with hemophilia. Steps 
have also been taken during manufacturing to increase the safety of recombinant factor products 
through improved protein purification, avoidance of all human or animal proteins,  and additional 
viral inactivation.23 
The widespread availability of safe factor replacements and implementation of 
prophylactic treatment of patients with hemophilia has enabled patients to maintain near normal 
lifestyles.24 Additionally, great progress has been made in the treatment of blood-borne viral 
infections such as antiretroviral treatment for HIV and combined ribavirin and α-interferon 
treatment for hepatitis C. All of this together has helped the hemophilia population by reducing 
morbidity and improving quality of life.25 The life expectancy of individuals with hemophilia, 
without viral infection, has greatly increased and is expected to be similar to that of the general 
population.26  
2.1.2  Molecular Genetics 
Hemophilia A is caused by pathogenic variants in the F8 gene located at Xq28. The F8 
gene is 186 kb long and has 26 exons.27 About 43-45% of individuals with severe hemophilia A 
have an intron 22 inversion in F8. About 2-5% of individuals with severe hemophilia A are found 
to have an intron 1 inversion.28 Almost all nonsense and frameshift pathogenic variants cause a 
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severe hemophilia A phenotype. Splice site variants most commonly result in a severe hemophilia 
A phenotype but can also be found in individuals with moderate or mild disease. Less than 20% 
of individuals with severe hemophilia A have a missense mutation while missense mutations are 
found in almost all cases of mild or moderate hemophilia A.9  It is estimated that about 60% of 
individuals with hemophilia A have a family history of the disease and the other 40% are sporadic 
cases. Of the sporadic cases, 90% of the mutations occurred in the affected individual’s parents or 
grandparents.29 In about 5% of cases of hemophilia A, a pathogenic variant cannot be identified in 
the F8 gene.30 
Hemophilia B is caused by mutations in the F9 gene located at Xq27. The F9 gene spans 
34 kb and has 8 exons.31 Over 1,000 mutations have been identified in F9 to cause hemophilia B. 
Over 70% of the reported pathogenic variants are point mutations and 16% are deletions. The 
remaining reported mutations are duplications, insertions, and combinations of insertions and 
deletions.32; 33 There have also been a few reports of large rearrangements in F9 that cause 
hemophilia B.34 Nonsense mutations, large deletions, and most frameshift mutations usually cause 
severe hemophilia B. Missense mutations can result in mild, moderate, or severe disease depending 
on the location of the specific nucleotide substitution.35 Some mutations that cause mild disease, 
such as c.1025C>T, have unusually high frequencies in certain populations, such as the Amish, 
due to the founder effect. It is estimated that 20-30% of cases of mild hemophilia B are due to 
founder effect mutations.36 It is estimated that up to 50% of cases of hemophilia Bare de novo, and 
the individual has no family history of disease.10 In families with sporadic hemophilia, 10% of 
cases are cause by somatic mosaicism. This can be difficult to detect and makes it hard to determine 
recurrence risks for a family.37 
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There is a rare subtype of hemophilia B called hemophilia B Leyden. Individuals present 
as hemophilia B in childhood, with low levels of Factor IX. After puberty their Factor IX levels 
begin to rise, and they often become asymptomatic.38 This rise in Factor IX activity is associated 
with increased androgen receptor and growth-factor activity.39 Point mutations in the promoter of 
F9 cause Hemophilia B Leyden.40 As of 2013, more than 80 families have been identified to be 
affected by hemophilia B Leyden.41  
An individual’s genotype can help determine their risk of inhibitor development. 
Individuals who have molecular defects that result in the complete absence of factor protein (i.e. 
large deletions, inversions, and nonsense mutations) have a higher likelihood to develop inhibitor 
than those who have a molecular defect that has some residual factor protein present (i.e. missense 
and splice site mutations).42 Individuals with an inversion of intron 22 in F8, the most common 
mutation that causes severe hemophilia A, are known to have a 20-30% risk of developing 
inhibitors.9 Individuals with a complete deletion of F9 are at a 50% risk of developing inhibitors 
while those with frame shift or nonsense mutations in F9 have a 20% risk.43 For those with 
missense mutations in F9, the risk for inhibitor development is almost zero.6 
2.2 Care for Individuals with Hemophilia 
2.2.1  Comprehensive Hemophilia Treatment Centers 
In 1975, the United States Congress established funding to create a national network of 
Hemophilia Diagnostic and Treatment Centers.44 Each of these centers had a blood bank, a 
coagulation laboratory, and a multidisciplinary hemophilia treatment team.45 There are currently 
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141 federally funded hemophilia treatment centers (HTCs) across the United States that have 
expanded to provide comprehensive care to individuals with many different inherited bleeding 
disorders, including hemophilia. HTCs in the United States are separated into eight geographic 
regions: MidAtlantic, New England, Great Lakes, Southeast, Northern States, Mountain States, 
Great Plains, and Western States. HTCs provide physical, emotional, psychological, educational, 
financial, and vocational support to their patients. The diverse care team at a HTC typically 
includes “hematologists, pediatricians, nurses, social workers, physical therapists, orthopedists, 
and dentists.”46 HTCs fulfill the American Academy of Pediatrics recommendations that children 
with special health care needs should have a medical home which is defined as care that is 
“accessible, continuous, comprehensive, family centered, coordinated, and compassionate.”47   
The Hemophilia Center of Western Pennsylvania (HCWP) is a state and federally funded 
HTC. HCWP is one of the sixteen HTCs that are located in the MidAtlantic region. It is one of the 
first established in 1975, after receiving federal funding. In 2001, HCWP established a clotting 
factor program through the federal 340B Drug Pricing Program. Through this program, clotting 
factor is purchased at a discounted Public Service rate and then used to fulfill patient factor 
prescriptions. The revenue generated from this program goes to support patient care and has 
allowed HCWP to expand its comprehensive care services.48 The care team at HCWP consists of 
pediatric and adult hematologists, nurses, social workers, a physical therapist, and a genetic 
counselor. Dr. Margaret Ragni has been a director of HCWP since 1988.49 
The HCWP has also actively participated in research since it was established. The center 
has a wide range of research endeavors available, from observational studies to NIH and 
pharmaceutical-sponsored drug trials and gene therapy studies.50 
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Patients who receive care at HCWP are recommended to have a yearly comprehensive 
evaluation where they are seen by members of the care team. This visit typically includes meeting 
with a hematologist, nurse, physical therapist, social worker, and insurance specialist. The 
appointment typically consists of a review of medical history, current medications, and upcoming 
elective surgical procedures. A physical exam is performed along with laboratory studies, and an 
assessment of thrombotic events and associated complications. Patients are also evaluated by the 
physical therapist and speak with the social worker and insurance specialist.51 
2.2.2  Prevention, Management, and Treatment 
Physical activity is encouraged in individuals with hemophilia, but with some restrictions. 
Non-contact sports are encouraged while high contact and collision sports should be avoided due 
to the risk of life-threatening bleeding that can be associated with injuries. During physical activity, 
target joints, or joints that experience frequent bleeding, should be protected with braces or splints. 
Individuals that chose to participate in physical activities that carry a higher risk of injury should 
prophylactically administer clotting factor prior to the activity.7  
The goal of treatment for hemophilia is to replace the missing clotting protein to prevent 
bleeds and in turn prevent long-term complications associated with hemophilia. Clotting factors 
come in two different types: plasma-derived and recombinant. Plasma-derived factor is derived 
from human plasma from human blood donations. Human blood carries a risk of transmitting 
infectious viruses such as hepatitis and HIV. Recombinant factor is artificially created in a lab and 
does not contain components derived from human blood, and therefore does not carry the same 
infectious risks.  
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There are a number of recombinant forms of factor VIII that have FDA approval to treat 
hemophilia A. These include Helixate, Reombinate, Kogenate, Advate, ReFacto, Elocate, and 
Xyntha. There are four plasma-derived factor VIII products available for the treatment of 
hemophilia A which are Monarc-M, Monoclate-P, Hemofil, and Koate-DVI.  
In 2017, the FDA approved Hemlibra (Emicizumab-KXWH), a bispecific antibody, for the 
treatment of hemophilia A. This medication is unique in its mechanism and that it is approved for 
the treatment of individuals with inhibitors. Hemlibra mimics factor VIII by binding to both 
activated factor IX and factor X which helps the blood to clot normally. Hemlibra prophylaxis 
safety and efficacy was evaluated in the HAVEN 1 trial. This was a Phase 3, open-label, 
multicenter, randomized trial that included 109 patients with hemophilia A who had inhibitors. In 
this trial, patients who received Hemlibra prophylaxis had an 87% reduction in annual bleed rate 
compared to those only given on-demand bypassing agents.52 
Individuals with mild hemophilia A also have the option of being treated with 
desmopressin (DDAVP) or antifibrinolytics (aminocaproic acid or tranexamic acid). DDAVP is a 
synthetic agent that is a derivative of vasopressin. This medication works by raising the level of 
factor VIII in the plasma and stopping bleeding. DDAVP can be administered via IV or nasal 
spray. Antifibrinolytics are medications that work by slowing clotting factor breakdown in the 
blood.  
There are also a number of recombinant forms of factor IX that have FDA approval for the 
treatment of hemophilia B. These include BeneFIX, Rixubis, Ixinity, Alprolix, Idelvion, and 
Rebinyn. AlphaNine SD and Mononine are the two factor IX plasma-derived concentrates 
currently on the market.  
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There are two main categories of factor replacement, episodic and prophylactic. Episodic, 
or “on demand” treatment, means that an individual only treats with factor replacement when there 
is clinically evident bleeding.7 Episodic treatment requires skill to evaluate the symptoms of a 
bleed and treat in a timely fashion.53 Prophylactic treatment means an individual treats with factor 
replacement on a consistent schedule to prevent anticipated bleeding.7 Prophylactic treatment can 
reduce the anxiety and alarm around physical trauma but this treatment regime carries ongoing 
psychological and organizational burdens.53 Prophylaxis has been shown to prevent bleeds and 
joint destruction which is important to preserve musculoskeletal function. Prophylactic treatment 
is useful in patients whose factor levels are less than 1 IU/dl (1%).7 There are no clear 
recommendations regarding how long patients should remain on prophylactic treatment.54  
Home therapy for patients with hemophilia is preferred. Home therapy allows for 
individuals to treat bleeds immediately which results in decreased dysfunction, pain, and long-
term disability.55 Home therapy also improves quality of life by giving individuals the flexibility 
to participate in physical activities and travel. Individuals who treat at home also miss less days of 
school/work and have greater employment stability.56 Home therapy needs to be done under the 
supervision of a comprehensive care team and can begin once an individual, and family, has been 
educated and trained about the treatment.57 Home therapy can even be initiated in young children 
as long as there is adequate venous access and trained family members. Some young children 
require an implanted venous access device to make administering treatment feasible.58 
2.2.3  Complications of Hemophilia 
A number of complications can occur in patients with hemophilia, especially in those not 
receiving adequate treatment. Repeated bleeding into joints with inadequate treatment can lead to 
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loss of function from muscle atrophy, loss of motion, joint deformity, pain, and contractures in the 
first or second decade of life.59 Chronic hemophilic arthropathy is the name used for this joint 
deterioration. This “process is set in motion by the immediate effects of blood on the articular 
cartilage during hemarthrosis and reinforced by persistent chronic synovitis and recurrent 
hemarthroses, resulting in irreversible damage.”7 With advancing cartilage loss, chronic 
hemophilic arthropathy leads to the development of muscle atrophy, angular deformities, and 
secondary soft tissue contractures. Chronic hemophilic arthropathy can be extremely painful and 
often requires ongoing treatment. The treatment used for chronic hemophilic arthropathy depends 
on the individual’s symptoms and stage of the condition. Typically, conservative techniques such 
as bracing, mobility, aids, and physiotherapy are used to manage the condition first. If conservative 
management techniques fail, surgical intervention may be needed.7  
Another musculoskeletal complication in hemophilia is synovitis. Synovitis is when the 
synovium of a joint becomes inflamed, hyperemic, and extremely friable after acute hemarthrosis. 
If acute synovitis is not treated, then it can result in repeated joint bleeds.59 A musculoskeletal 
complication that is unique to hemophilia is the development of pseudotumors which can be limb 
and life-threatening. Pseudotumors develop from an inadequately treated soft tissue bleed, 
typically in muscle adjacent to bone. If untreated, pseudotumors can grow very large, put pressure 
on adjacent neurovascular structures, cause fractures, and lead to the development of a fistula 
through the overlying skin.7 
In the current treatment era, the most severe treatment-related complication is inhibitor 
development in individuals with hemophilia.7 Inhibitors refers to IgG antibodies that neutralize 
clotting factors. Inhibitors cause treatment with replacement factor to be impossible because the 
inhibitory antibody blocks and clears the infused factor. Thus, it is recommended that all 
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individuals be screened for the presence of inhibitors.7 Development of inhibitors is more common 
in hemophilia A compared to hemophilia B. Approximately 20-30% of individuals with severe 
hemophilia A and 5-10% of individuals with mild or moderate hemophilia A will develop 
inhibitors in their lifetime.60 Comparatively, less than 5% of individual with hemophilia B develop 
inhibitors in their lifetime.6 It is important to note that up to 50% of individuals with hemophilia 
B and inhibitors have severe allergic reactions, including anaphylaxis, when factor IX is 
administered. Due to this complication, individuals with hemophilia B should be given factor IX 
concentrates in a clinic or hospital setting for their first 10-20 treatments in case of an allergic 
reaction.61 Inhibitors in individuals with severe hemophilia A can be eradicated using immune 
tolerance induction therapy. Experience with this therapy is limited in hemophilia B and can cause 
other complications so immunosuppressive therapies can be considered in these individuals.62; 63 
Another complication of hemophilia, albeit more historically, is risk of contracting 
transfusion-transmitted infections. Before the availability of recombinant factor, plasma-derived 
factor was widely used, which carries the risk of infection. Many individuals with hemophilia 
contracted HIV and/or a form of hepatitis by receiving plasma-derived clotting factor. Individuals 
that contract one of these infections also have to deal with the complications associated with these 
viruses and require special treatments. 
2.3 Transition of Care From Pediatric to Adult Care Providers 
Health care transition is defined as the of changing from a pediatric to adult health care 
model care. In recent years, this transition of care has become a significant issue due to an aging 
population. Over 90% of individuals with severe disabilities are now living into adulthood and 
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need continuation of appropriate healthcare services, which are often more complex.64 Health care 
transition has been a growing area of research and a number of policy statements have been 
published that address how it should be performed.  
In 2002, the American Academy of Family Physicians, American Academy of Pediatrics, 
and American College of Physicians-American Society of Internal Medicine published a joint 
policy statement about the transition of care for young adults with chronic health conditions. This 
outlined that “the goal of transition in health care for young adults with special health care needs 
is to maximize lifelong functioning and potential through the provision of high-quality, 
developmentally appropriate health care services that continue uninterrupted as the individual 
moves from adolescence to adulthood.”1 The organizations supporting this statement wanted all 
primary care and subspecialty physicians who work with young adults with special health care 
needs to have a better understanding of transition. Specifically they wanted physicians to “1) 
understand the rationale for transition from child-oriented to adult oriented health care; 2) have the 
knowledge and skills to facilitate the process; and 3) know if, how, and when transfer of care is 
indicated.”1 The statement emphasizes the importance that individuals receive developmentally 
appropriate care from a physician trained in the medical care of adults.  
The statement also goes on to detail six steps to ensure the transition to adult-oriented 
health care is successful for this patient population. The first step indicates that all patients should 
have an identified health care professional that can assume responsibility for their health care as 
they reach adulthood. The next step is that physicians and medical residents receive training on 
how to “provide developmentally appropriate health care transition services to young people with 
special health care needs.”1 The third step addresses the development of a medical summary that 
is up-to-date for each patient that can provide a knowledge base for all health care professionals 
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involved in a patient’s care. Next, a written health care transition plan should be created with the 
patient and family that details what health care services are needed, who will provide the services, 
and how the services will be paid for. There should be a minimum of annual plan updates. The 
fifth step outlines that all patients with special health care needs should be cared for following the 
same guidelines for primary and preventative care that are used for all adolescents and young 
adults, but it should be recognized that these individuals may need more resources and services. 
The final step indicates that continuous health care coverage should be ensured throughout 
adolescence and adulthood.1 
In 2011, the same organizations updated their policy statement about transition, and 
expanded it to include youth without special health concerns.65 Shortly after, the “Six Core 
Elements of Health Care Transition” was developed as a structured process that can be customized 
to different situations and applied to many different transition of care models. Three different 
version of the Six Core Elements have been created: for pediatric practices, for adult practices, and 
for clinicians who care for individuals throughout their lifespan. Additionally, two process 
measurement tools and a feedback measurement tool have been developed to evaluate the Six Core 
Elements. All of the Six Core Elements of Health Care Transition information is available for 
public access on gottransition.org. This resource also outlines a recommended health care 
transition timeline.  
Following the updated policy statement, a study was done to evaluate what proportion of 
the United States youth, ages 12 to 17, were receiving transition planning. This study surveyed the 
parents and/or caregivers of 20,708 youth to determine if transition planning occurred. The survey 
evaluated transition planning by asking about the following elements: 1) if the health care provider 
discussed the change to an adult healthcare provider, 2) if the health care provider helped the youth 
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gain self-care skills or helped them understand the health care changes at age 18, and 3) if the 
youth had time alone with the health care provider during the last preventive care visit. Individuals 
that met all three of the outlined measurements were said to meet the overall transition measure. 
The researchers found that “17% of youth with special health care needs and 14% of youth without 
special health care needs met the overall transition measure.”66 After this study was published, an 
updated policy statement was published in 2018 which includes more practice-based quality 
improvement guidance.67  
2.3.1  Challenges During Transition of Care 
As research related to transition expands, more adverse effects of transition have been 
revealed. Individuals who lacked a structed health care transition have shown higher rates of 
medical complications,68 discontinuity of care,69 problems with treatment and medication 
compliance,70 higher hospital and emergency department use,71 and higher costs of medical care.72  
Another growing area of research has investigated the barriers to an effective transition. 
One of the largest barriers to transition that patients and families cite is the fear of leaving their 
pediatric clinicians for a new physician and possibly new health care system.73 Another barrier is 
inadequate planning for the transition, especially in individuals without special health care needs. 
A 2017 study showed that youth with special health care needs had higher levels of transition 
readiness which included completing more medical tasks independently, with less parent 
involvement, compared to their peers without chronic medical conditions.74 System difficulties 
such as finding specialized adult clinicians, transferring medical records, and insurance coverage 
are other barriers that have been reported by patients and families.73 
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Health care providers have noted some of the same barriers to transition such as lack of 
communication between pediatric and adult physicians and between health care systems. Another 
barrier is limitations in training. Specifically, limited training in pediatric-onset conditions, caring 
for adult patients who are reliant on their caregivers, and adolescent development and behavior. 
Pediatric clinicians often cite the lack of adult clinicians willing to treat patients with pediatric-
onset conditions as a barrier.75 Adult clinicians note that they need improved infrastructure in the 
form of care coordination and community resources to care for individuals with pediatric-onset 
conditions.76 
2.3.2  Challenges During Transition of Care in Patients with Hemophilia  
In addition to the normal challenges that can be experienced during the period between 
adolescence and adulthood, patients with hemophilia have added challenges due to their disease. 
During this time, patients usually have to adapt their lifestyle due to hemophilia, transition their 
care from pediatric to adult care services, and eventually take full responsibility for management 
of their hemophilia. Taking full responsibility for hemophilia management includes many aspects 
including self-infusions, ordering supplies, attending clinic appointments, maintaining treatment 
adherence, and navigating the insurance system.77 
A Scandinavian survey investigated the transition of hemophilia management from parent 
to child. They found that age 14 was the average age that patients take over responsibility for their 
treatment, but at age 17.2 years, almost 25% of participants needed help from their parents for 
their hemophilia-related care. This finding suggests that parents of individuals with hemophilia 
often play a role in medical management, even after age 18.  
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This same study also looked at treatment compliance. They reported that 41% of the 
hemophilia patients, aged 13 to 25, did not follow their prophylaxis regimen as prescribed.77 Poor 
prophylaxis compliance has been seen in other research. An international survey of 147 hemophilia 
treatment centers showed a significant decrease in prophylaxis adherence between age groups. In 
the 0-12 age group, 59% of patients had over 90% prophylaxis adherence compared to 13% with 
this level of adherence in the 13-18 age group and 6% in the 19-28 age group. The health care 
providers survey cited multiple reason for decreased compliance including: “inability to 
understand potential benefits, denial, poor venous access, lack of parent/family commitment, 
interference with lifestyle, teenage rebellion, and lack of time.”78 Decreased prophylaxis adherence 
in adolescence has the potential to lead to recurrent joint bleeds, which impact lifelong medical 
complications and quality of life. 
2.3.3  Transition Recommendations in Hemophilia  
In the early 2000s, the National Hemophilia Foundation created the “Transition Task 
Force” to develop transition guidelines that could be used with children who have bleeding 
disorders by the HTC care team. The task force succeeded in developing transition guidelines for 
members of the healthcare team such as nurses, physicians, physical therapists, social workers, 
and genetic counselors who provide care for patients with bleeding disorders. The developed 
transition guidelines are age-specific and address items from birth to 18 years of age. The goals 
and objectives at each age group are divided into five sections: social support, health and lifestyle, 
educational/vocational/financial planning, self-advocacy and self-esteem, and independent health 
care behaviors. Each goal/objective has listed strategies for the health care providers to use to meet 
 21 
the goal. The Transition Task Force also developed review questions for each age group included 
in the transition guidelines.  
In 2012, transition recommendations were published in the journal Haemophilia. These 
recommendations divide the lifespan into six age categories: infancy, toddler years, early school 
years, middle school years, teen years, and adulthood. The recommendations outline the medical 
and psychosocial transitional issues for each age category. This paper encourages a “well-
developed transition plan from birth to adulthood” that “facilitates the necessary change from total 
dependence on caregivers to complete independence by the time one reaches 18 years of age.”79 
During the teen years, it is recommended that individuals with hemophilia become fully 
independent in their care, which includes ordering, mixing and self-administering factor. It is also 
recommended that the health care team reviews bleed recognition and early treatment along with 
an emphasis on continuing prophylactic treatment. The main psychosocial aspects of transition 
during the teen years are the disclosure of the disease to others and the shift of responsibility from 
parent(s)/guardian(s) to the patient. It is recommended that the healthcare team help patients 
navigate through the consideration of when and how to disclose their diagnosis to friends and 
significant others. This article highlights that the main medical challenges in adulthood are the 
decision to continue or discontinue prophylaxis, the management of joint disease and other 
complications, and finding an appropriate primary care physician. During adulthood, the challenge 








Hemophilia is an X-linked inherited coagulation disorder. Hemophilia A is the result of 
Factor VIII deficiency, and hemophilia B is the result of Factor IX deficiency. These deficiencies 
are caused by pathogenic variants in F8 and F9, respectively. The prevalence of hemophilia A is 
estimated at 1:6,500 live male births, and the prevalence of hemophilia B is estimated at 1:30,000 
live male births in the United States.3; 4 Hemophilia severity is classified based on the factor 
concentration in the blood and symptoms differ based on severity. Individuals with severe 
hemophilia (less than 1% factor level) typically have spontaneous bleeding into joints and muscles, 
while individuals with moderate hemophilia (1 to 5% factor level) have occasional spontaneous 
bleeding and prolonged bleeding with minor trauma. Individuals with mild hemophilia (greater 
than 5% factor level) usually only have severe bleeding with major trauma.6 
Originally, hemophilia was treated with blood transfusions and then with cryoprecipitated 
factor from plasma. In the 1980s, recombinant factor products began to be manufactured and have 
become the mainstay of hemophilia treatment.21 The goal of hemophilia treatment is to replace the 
missing clotting factor to treat and prevent bleeds and complications associated with hemophilia. 
Individuals may receive episodic treatment, where they only use factor replacement when there is 
evident bleeding. Others receive prophylactic treatment, where they administer factor replacement 
on a consistent schedule to prevent anticipated bleeding.7 The treatment advancements of 
recombinant factor and prophylactic treatment, have led to an improved quality of life and reduced 
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morbidity in the hemophilia population.25 The life expectancy of individuals with hemophilia has 
greatly increased and is expected to be similar to the general population.26 
While the life expectancy of individuals with hemophilia has increased, there are still 
several complications that may occur. Individuals may develop a “target joint,” or a joint where 
they experience recurrent episodes of hemarthrosis, which can result in permanent damage to the 
joint and hemophilic arthropathy. Hemophilic arthropathy typically develops in the second decade 
of life. This can result in secondary muscle atrophy, soft tissue contractures, and angular 
deformities of the joint which can be extremely painful.7 
Inhibitor development is another major complication and refers to the development of IgG 
antibodies that neutralize clotting factors. This can lead to increased bleeding, as factor 
replacement is no longer effective. Approximately 20-30% of individuals with severe hemophilia 
A and approximately 5-10% of individuals with mild or moderate hemophilia A develop inhibitors 
in their lifetime.60 Less than 5% of individuals with hemophilia B develop inhibitors in their 
lifetime.6 
Individuals with hemophilia require specialized lifelong care. In 1975, the United States 
developed a national network of Hemophilia Diagnostic and Treatment Centers for the care of 
individuals with hemophilia.44 The Hemophilia Center Western Pennsylvania (HCWP) is one of 
the 141 federally funded hemophilia treatment centers. The HCWP provides physical, emotional, 
psychological, educational, financial, and vocational supports to its patients with a diverse team of 
care providers including pediatric and adult hematologists, nurses, social workers, a physical 
therapist, and a genetic counselor. Individuals with hemophilia, cared for by HCWP, are 
recommended to have yearly comprehensive clinic visits. These visits typically include meeting 
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with multiple members of the care team including a hematologist, nurse, physical therapy, social 
worker, genetic counselor, and insurance specialist.  
Now that individuals with hemophilia have an expected normal lifespan, they must 
transition from being seen by pediatric to adult health care providers. At the HCWP, patients 
continue to be seen at the same clinic location, but they transition from a pediatric to an adult 
hematologist. Additionally, as patients age into adulthood, they need to take over full responsibility 
for the management of their condition. This includes many aspects such as self-infusion, ordering 
supplies, attending clinic appointments, maintaining treatment adherence, and navigating the 
insurance system.77 Previous research about the transition of care in individuals with hemophilia 
has found decreased prophylaxis adherence during this period. Additionally, research has found 
that parents often play a role in medical management of their child’s hemophilia after age 18.77  
Overall, research about transition of care in hemophilia is limited. In this study we aim to 
evaluate the impact of transition of care from pediatric to adult health care providers in patients 
with hemophilia who are treated at the HCWP. This study specifically focused on how 
comprehensive visit compliance and bleeding events are impacted by transition of care while also 
assessing lapses in insurance coverage.  
3.2 Methods 
The participants for this study were chosen from the pool of adult patients diagnosed with 
hemophilia A or hemophilia B who are cared for at the Hemophilia Center of Western 
Pennsylvania (HCWP). The participant population included male patients ranging from age 26 to 
age 30, as of October 1, 2019, and currently being cared for HCWP. Participants of this age were 
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included as they are of a post-transition of care age and have had access to similar treatment 
products and clinical care guidelines. Participants were excluded if they had not received at least 
5 consecutive years of treatment at the HCWP.  Male participants with all severities of hemophilia 
were included in the study.  
3.2.1  Data Collection 
The data were collected from electronic and paper medical records and coded. Data were 
collected starting at age 15 for each participant. If participants, were not yet enrolled in the HCWP 
program when age 15, data was recorded from the year they became patients at HCWP. 
Demographics including sex, age, and ethnicity were collected. Previous laboratory studies were 
used to determine hemophilia type and severity. Individuals with <1% factor activity were 
classified as severe. Moderate disease was classified as individuals with 1-5% factor activity. 
Those with >5% factor activity were classified as mild.  
Each participant’s medical record was evaluated to ascertain any lapses in insurance. A 
participant was said to have a confirmed lapse in insurance if any nursing note or social work note 
said that the patient either had no insurance coverage or had a period of time where they did not 
have coverage. Additionally, when the patient registration noted they were self-pay, they were said 
to have no insurance at this time.  
Joint disease complications and inhibitor development was determined for each participant. 
Joint disease status was determined by the presence of a target joint or hemophilia arthropathy 
recorded in any comprehensive visit or physical therapy note, from age 15 to 30. To determine 
inhibitor development at any point, Bethesda inhibitor titer results were used, as well as 
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comprehensive visit notes that mentioned inhibitor or a history of inhibitor that had previously 
been tolerized.  
Comprehensive visit compliance was determined for every age, beginning at age 15 or 
when they became patients at HCWP. Comprehensive visit compliance was not determined for the 
current age of each patient, as they still have time to complete this annual comprehensive visit for 
their current age. Patients who had a yearly comprehensive appointment at HCWP were recorded 
as being compliant. Additionally, the presence of bleeding, including joint and soft-tissue bleeding, 
was determined for each age. Bleeding was determined by looking at comprehensive visit notes, 
physical therapy notes, and patient calls to HWCP about bleeding. If any of these sources of 
medical information mentioned the presence of traumatic or non-traumatic bleeding, then it was 
recorded as bleeding for that year.  
3.2.2  Statistical Analysis 
Descriptive statistics were conducted to determine the average age of participants, rates of 
hemophilia type and severity, lapses in insurance coverage, joint disease and inhibitor rates. These 
were calculated using Microsoft Excel. Two sample t-tests with equal variances were done to 
determine if joint disease or inhibitor development varied based on hemophilia severity. The same 
statistical analysis was performed to see if joint disease or inhibitor varied based on hemophilia 
type. All t-tests were performed using StataSE 15.  
For ages 15 through 29, the proportion of participants that were compliant with 
comprehensive visits and the proportion of participants that had bleeding were calculated. Using 
these proportions, linear regression analyses were performed to assess the linear relationship 
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between age and comprehensive visit compliance and age and bleeding events. These analyses 
were performed using StataSE 15. 
This study was approved by the University of Pittsburgh IRB. A copy of the approval can 
be found in Appendix A.  
3.3 Results 
3.3.1  Participant Demographics and Disease Characteristics  
A total 40 male patients with hemophilia, aged 26-30 years old, were being treated at 
HCWP as of October 1, 2019. Only 26 of these patients had at least 5 consecutive years of 
treatment at HCWP and were included in this study. Fourteen patients were excluded because they 
had recently established care at the HCWP and had not been under the care of the HCWP for at 
least 5 years. The mean age of the 26 participants was 27.73 years. Nine (34.6%) of the participants 
had hemophilia B while the other 17 (65.4%) had hemophilia A. Fourteen (53.8%) of the 
participants had hemophilia that was categorized as severe and the other 12 (46.2%) had 
hemophilia that was categorized as mild or moderate. The ethnicity of 23 of the participants was 
classified as white; the other 3 ethnicities were classified as African American, Hispanic, and other.  
All the participants were receiving either recombinant factor or Hemlibra as treatment 
throughout the time period studied. Only one participant was documented to have received human 
blood products during the time period studied. The administration of human blood products to this 
participant was due to a serious traumatic injury.  
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Table 1: Participant demographics and disease characteristics 
 
 
3.3.2  Insurance 
Medical records were reviewed to determine insurance coverage from age 15 to age 30. 
Based on the medical records reviewed, eleven (42.3%) of the 26 participants were found to have 
at least one confirmed lapse in insurance coverage during this age period. All of the confirmed 
lapses occurred after age 18 in this cohort.  
3.3.3  Joint Disease and Inhibitor  
Medical records were used to assess the presence of joint disease. Seventeen (65.4%) 
participants had documented joint disease. The presence or history of inhibitor was evaluated 
through review of medical records. Five (19.2%) participants were found to have inhibitor. All 
participants in this study that had inhibitor had hemophilia A. A two-sample t-test with equal 
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variances was used to evaluate the relationship between joint disease and hemophilia severity. No 
difference was found in joint disease with severe hemophilia compared to those with 
mild/moderate hemophilia (p-value=0.36). A two-sample t-test with equal variances was also used 
to evaluate if inhibitor development varied by severity of hemophilia. No difference was found in 
inhibitor development with severe hemophilia compared to those with mild/moderate hemophilia 
(p-value=0.21).  
The same statistical analyses were performed to evaluate the relationships between joint 
disease and hemophilia type, as well as inhibitor development and hemophilia type. No difference 
was found in joint disease with hemophilia A compared to hemophilia B (p-value=0.44). A 
statistically significant difference was found with inhibitor development by hemophilia type (p-
value=0.02). A correlation analysis was done between joint disease and inhibitor development. 
The Pearson correlation coefficient was 0.355 with a p-value of 0.08. We do not have evidence to 
suggest that there is a correlation between joint disease and inhibitor development in this study.  
 




3.3.4  Age, Comprehensive Visit Compliance, and Bleeding 
Yearly comprehensive visit compliance and presence of bleeds were determined for each 
participant from age 15, or when they became patients at HCWP. Visit compliance and bleeds 
were not determined for their current year of age, as the full calendar year has not been completed 
for these measures. The proportion of participants who were compliant with their comprehensive 
visit was calculated for each age from 15 to 29. A linear regression analysis was performed to 
evaluate the relationship between age and comprehensive visit compliance. The estimated slope 
was found to be -0.004 with a confidence interval from -0.02 to 0.012. This means that for every 
1 year increase in age, there was a 0.004 decrease in the proportion of participants with 
comprehensive visit compliance. The p-value for this analysis was 0.59, so this result was not 
statistically significant. Based on this analysis, we do not have evidence to suggest that age has a 
linear relationship with comprehensive visit compliance in this study.  
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Figure 1: Comprehensive visit compliance by age 
 
The proportion of participants that had bleeding each year was calculated for each age from 
15 to 29. A linear regression analysis was performed to evaluate the relationship between age and 
bleeding. The estimated slope was found to be 0.00011 with a confidence interval of -0.0145 to 
0.0148. This means that for every 1 year increase in age, there was a 0.00011 increase in the 
proportion of participants with bleeding. The p-value for this analysis was 0.987, so this result was 
not statistically significant. Based on this analysis, we do not have evidence to suggest that age has 
a linear relationship with bleeding in this study.  
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Figure 2: Bleeding by age 
3.4 Discussion
3.4.1  Insurance 
In this study, we identified that many individuals with hemophilia have lapses in their 
insurance coverage. Specifically, we found that 42.3% of the participants had lapses in insurance, 
all of which were after age 18. In Pennsylvania, all children can get insurance coverage, the type 
of coverage depends on a family’s income, which is likely why insurance lapses occurred only 
after age 18. Children can either receive health insurance through the Children’s Health Insurance 
Program (CHIP) or medical assistance. Once a child turns 19, they are no longer eligible to be 
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covered by CHIP. Individuals may also have lapses in their insurance when they turn 26 and can 
no longer be covered under their parent’s health insurance.  
We found a higher rate in lapses in insurance coverage compared to what has been reported 
in the literature. In 2015, a study was published that examined the demographics, comorbidities, 
and health status of young adults with hemophilia in the United States. This study included 141 
men aged 18-35 years old who received care at hemophilia treatment centers between 2005 and 
2013. They found that the uninsured rate in their cohort was 9.9% which is lower than the 
uninsured rate of the general United States adult population.80  
3.4.2  Joint Disease and Inhibitor 
This study did not find a significant difference in joint disease between severe hemophilia 
and mild/moderate hemophilia. This was an unexpected result. Previous research has shown that 
as factor activity decreases, the number of joint bleeds increase. This means that those with severe 
disease have higher rates of joint bleeds which increases their likelihood of developing joint 
disease. Based on this, we expected to see a difference in joint disease present between hemophilia 
severity.81 We may not have observed this difference because joint disease development can be 
influenced by other factors such as prophylactic or episodic therapy, age, and weight which were 
not taken into account in this analysis.  
In this study, we found that there was not a significant difference in joint disease between 
hemophilia A and hemophilia B, which is in contrast to what has been reported in the literature. 
Other studies in the literature have investigated the differences in the need for joint arthroplasty 
between types of hemophilia. These studies used joint arthroplasty as an indirect measure of joint 
arthropathy, as severe cases of arthropathy often require arthroplasty. In these studies, individuals 
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with hemophilia A underwent about three times more joint arthroplasties than those with 
hemophilia B. This finding has been consistent across multiple nationalities.82 We may not have 
observed this finding because we were measuring the presence of any severity joint disease, rather 
than focusing on severe joint disease that requires arthroplasty.  
Additionally, we found that there was not a significant difference in inhibitor development 
between individuals with severe hemophilia compared to those with mild/moderate hemophilia. 
This finding contradicts other studies that have evaluated inhibitor development and disease 
severity. Other studies have found that rates of inhibitor development are lower among individuals 
with mild or moderate hemophilia compared to those with severe hemophilia. Inhibitors are 
thought to be more common in individuals with severe hemophilia because these individuals are 
more likely to have no or truncated protein. Comparatively, individuals with mild or moderate 
disease are tend to have trace amounts of protein which can result in immune tolerization.83 This 
difference may not have been observed in our study due to our small sample size.   
As we expected, we found that there was a significant difference in inhibitor development 
between the types of hemophilia with 29.4% of individuals with hemophilia A developing 
inhibitors compared to 0% of individuals with hemophilia B. This finding was expected as 
numerous studies have shown that inhibitor development is more common in individuals with 
hemophilia A than hemophilia B. Specifically, about 30% of individuals with severe hemophilia 




3.4.3  Age, Comprehensive Visit Compliance, and Bleeding 
Hemophilia is a lifelong hematologic condition that requires continual care throughout an 
individual’s lifespan. This study was done to investigate the impact of the transition of care from 
pediatric to adult care providers in a cohort of males that receive treatment at the HCWP. Previous 
studies have shown that this transition has a negative impact on prophylaxis compliance, but no 
studies have investigated the impact on clinic attendance or the presence of bleeding.78  
This study focused on a cohort of males age 26-30 and looked retrospectively at their 
medical records from an age before transition to their current age at the time of the study. We did 
not find a linear relationship between age and bleeding. Previous research has shown that 
prophylaxis regimen compliance decreases when an individual is transitioning care.77 Based on 
this previous research, we would have predicted bleeding to increase with age as prophylaxis 
compliance has been shown to decrease. We may not have seen this trend because we were 
studying a cohort that included individuals with a mix of episodic and prophylactic treatment. 
Additionally, this trend may not have been observed due to the small sample size in this study.  
We did not find linear relationship between age and comprehensive visit compliance in our 
cohort. While there is not a relationship, comprehensive visit compliance is lower than the HCWP 
goals for their patients. Ideally, all individuals should be seen annually for their comprehensive 
visit. Previous research has shown that individuals that attend less than one visit per year at a 
hemophilia treatment center have higher rates of emergency department visits and hospitalizations 
compared to patients that never missed appointments.84 This means that poor comprehensive visit 
compliance can result in more complications for patients with potentially life long impacts.  
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3.4.4  Limitations 
Several limitations exist in this study. One of the limitations is that the data were collected 
retrospectively using electronic and paper medical records. Only information included in the 
medical records was able to be collected. The medical records contained a number of gaps in 
information that were collected. For instance, HCWP used an electronic medical record system 
called Medinotes from 2009 to 2014. Medinotes only contained the comprehensive visit notes, and 
some social work and physical therapy notes. Medinotes did not contain other information that 
Centricity and the paper medical records contained such as factor prescriptions, phone call records, 
and registration information. This resulted in some gaps of information about insurance coverage.  
Another limitation is small sample size. This study only had 26 participants, which is 
relatively small. Additionally, not all of the participants were patients at HCWP from age 15. This 
combined with the gaps in data, means that not every age had data on all 26 participants, making 
the sample size at each age even smaller.  
Fourteen patients, age 26-30, were excluded from this study as they did not have at least 
five consecutive years of treatment at the HCWP. Since 35% of the total male hemophilia patients 
age 26-30 at the HCWP were excluded in this study, this sample may not be representative of the 
entire HCWP hemophilia patient population.  
3.4.5  Future Studies 
Previous studies have found the adherence to prophylactic therapy decreases as individuals 
age into adolescence and into adulthood. A decrease in prophylactic therapy can lead to increases 
in bleeding, which can result in long-term joint damage. Our study did not specifically evaluate 
 37 
treatment adherence to either episodic or prophylactic treatment. A future avenue of research 
would be to evaluate the impact of transition from pediatric to adult care providers on treatment 
adherence. This would also allow additional analyses to assess the relationship between changes 
in treatment adherence and bleeding episodes.  
Future research could focus on identifying barriers to clinic attendance at HCWP as 
patients age into adulthood. This could be done by surveying patients at the hemophilia center to 
determine the existing barriers to clinic attendance. There is a paucity of literature on this topic 
and this new information should help to identify and characterize barriers; then new interventions 
can be established to attempt to minimize these barriers, improve clinic attendance, medical 
adherence and quality of life.  
Insurance coverage is another important issue that should be further studied. This study 
found that 43.2% (11/26) of the participants had at least one confirmed lapse in insurance coverage. 
Insurance coverage is needed by most individuals to help pay for their hemophilia-related medical 
expenses such as factor prescriptions, clinic visits, and laboratory studies. Further research could 
evaluate the specific barriers that  patients experience when losing and obtaining insurance 
coverage. Through identification of these barriers, interventions can be developed to try and 
improve insurance coverage in this population. Improved insurance coverage has the possibility 
of increasing comprehensive clinic adherence, medication adherence, and decreased rates of 
hemophilia complications such as joint disease.  
3.4.6  Lessons Learned 
Through the data collection of this study, we gained insight about the medical records at 
the HCWP. The major lesson learned was that there is a lack of standardization in the physician’s 
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comprehensive visit notes. When formulating this study, we planned to determine the number of 
bleeding episodes participants had annually, as well as their treatment compliance. Once medical 
record review began, it was discovered that collecting this detailed level of data would not be 
possible, mainly because this information was not consistently included in the physicians’ notes. 
Some of the physician notes included information about whether a patient experienced any 
bleeding events in the past year, but often vague terms were used, such as “some bleeds,” or 
“occasional bleeding events.” This terminology conveys that bleeding is present, it but does not 
quantify the amount of bleeding that took place. Additionally, the physician notes often did not 
differentiate between joint and soft tissue bleeds. This is an important differentiation to include, as 
these different bleed types result in different complications.  
The physician’s notes rarely included information about the patient’s treatment 
compliance. A patient’s treatment compliance can be estimated based on talking with the patient, 
the presence of bleeds, and factor replacement usage. The new electronic medical record system 
used by the HCWP includes information about when a patient refills their factor prescription, so a 
physician can use this data as a proxy for treatment compliance. Having information about 
treatment compliance could be helpful for all members of the care team to be aware of and could 
be a beneficial variable to look at in future studies.  
3.5 Conclusion 
This study adds to the body of research regarding the impact of transition of care from 
pediatric to adult providers in the hemophilia population. It offers insight about how 
comprehensive visit compliance and bleeding is impacted. In this small study, we found that age 
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did not have an impact on comprehensive visit compliance and bleeding. Additionally, this study 
showed that many of the patients with hemophilia have lapses of health insurance coverage over 
the age of 18. Further research could help determine effective ways to improve comprehensive 
visit attendance and health insurance coverage.  
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4.0 Significance to Genetic Counseling and Public Health 
One of the three core functions of public health is assessment. This is defined as the 
monitoring and diagnosing of health problems in the community. HCWP uses annual 
comprehensive clinic visits to monitor the health of individuals with hemophilia. This study did 
not find an association between age and comprehensive visit compliance, but the study did show 
that comprehensive visit compliance is less than ideal at all ages at the HCWP, averaging only 
63.5%. Comprehensive visits are important in ensuring patients are receiving an adequate 
replacement factor dosage which is critical for the effective treatment or prevention of bleeds. 
Additionally, these appointments allow the healthcare team to identify a variety of complications 
of hemophilia such as inhibitor development and hemophilic arthropathy. Often during these 
comprehensive visits patients meet with social workers to evaluate how they are coping with their 
diagnosis and help them navigate other difficulties that may come with hemophilia such as 
insurance coverage and getting appropriate accommodations that may be needed at school or work. 
One complication that is important to identify early is hemophilic arthropathy as it can 
have major impacts on the quality of life of individuals with hemophilia. Hemophilia arthropathy 
can be very painful and cause joint contractures/deformity which can interfere with daily activities. 
This can also result in individuals with hemophilia missing work and school. Individuals are 
evaluated for hemophilic arthropathy at their annual comprehensive visits in order to identify and 
treat early and prevent progression. When hemophilic arthropathy is identified at an early stage, 
conservative treatments can be used to try and manage the pain and maintain function of the joint. 
If conservative measures fail, then individuals may require surgical interventions to manage the 
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arthropathy.7 Surgical interventions are often more costly to the healthcare system and require 
additional time of work and/or school for recovery. 
Individuals with hemophilia usually have their inhibitor levels checked at their annual 
comprehensive clinic visits. It is important for inhibitor development to be identified and treated 
in a timely manner. When inhibitor develops, individuals no longer respond to their replacement 
factor, and may even have an anaphylactic reaction to the factor. This can cause individuals to 
have more frequent bleeding which increases the risk of severe complications. Determining ways 
to increase comprehensive visit compliance has the possibility of improving the long-term health 
of individuals with hemophilia and reduce the health care costs of hemophilia treatment.  
The assessment of individuals with hemophilia through comprehensive visits is also 
important in decreasing healthcare costs associated with hemophilia. A previous study evaluated 
non-attendance among patients at hemophilia treatment centers from 2010-2014. They found the 
individuals who attended less than one visit per year had higher rates of emergency department 
visits and hospitalizations compared to patients that never missed appointments.84 These increases 
in emergency department visits and hospitalizations increases the healthcare costs for these 
patients which can be a cost to the patient and society. It is estimated that one third of patients with 
hemophilia are covered by Medicaid which means the care is funded by the state.85  
The costs of treatment associated with hemophilia is a huge burden economically for 
patients, healthcare systems, and society as a whole. It is estimated that the mean healthcare costs 
for a patient with hemophilia, with the absence of inhibitors, is $140,000 per year. Over 80% of 
this direct expenditure is the cost of factor replacement therapy. The costs of treatment for 
hemophilia with the presence of inhibitor can be five times greater than treatment without inhibitor. 
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Additionally, patients with inhibitor are more likely to visit the emergency department and more 
likely to require inpatient hospital stays.85  
An essential service of public health is educating individuals about their health issues. The 
National Hemophilia Foundation Transition Guidelines recommend that all individuals with 
hemophilia, or who are carriers of hemophilia, understand the implications of the diagnosis 
between ages 16 to 18. This should include education about how hemophilia is inherited. During 
the transition years, patients may be begin thinking about having children and should be aware of 
the inheritance risks. Patients with hemophilia should be educated that all of their daughters will 
be obligate carriers of hemophilia and that 30% of carrier females are symptomatic. They should 
know that they cannot pass on hemophilia to any male children. It is important for patients to be 
aware of these risks prior to having children in case it would impact their reproductive decisions. 
This study revealed that age does not appear to have an impact on comprehensive clinic attendance, 
but overall attendance is lower than the HCWP would like. Knowing that comprehensive visit 
attendance is low it may be beneficial to determine alternate methods for genetic counselors to 
provide this information to patients that fail to attend their comprehensive visits.  
The genetic counselor at the HCWP plays an integral role in the care of patients with 
hemophilia. Other hemophilia treatment centers also have genetic counselors as a part of their 
comprehensive care team. These genetic counselors are involved in many aspects of hemophilia 
patient care including genetic testing, carrier testing, reproductive counseling, and education about 
hemophilia. This study showed transition did not have an impact on comprehensive visit 
compliance, but overall visit attendance is lower than desired. Additionally, this study found that 
65.4% of the cohort have joint disease. These are important areas where genetic counselors can 
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work with patients to educate them on the importance of comprehensive visit compliance as well 
as proper treatment adherence to help prevent the development of joint disease.  
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